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Abstract
Background: Neuroblastic tumors account for 9–10% of pediatric tumors and neuroblastoma (NB) is the first cause of death
in pre-school age children. NB is classified in four stages, depending on the extent of spreading. A fifth type of NB, so-called
stage 4S (S for special), includes patients with metastatic tumors but with an overall survival that approximates 75% at five
years. In most of these cases, the tumor regresses spontaneously and regression is probably associated with delayed
neuroblast cell differentiation.
Methodology/Principal Findings: In order to identify new early markers to follow and predict this process for diagnostic
and therapeutics intents, we mimicked the differentiation process treating NB cell line SJ-NK-P with all-trans-retinoic acid
(ATRA) at different times; therefore the cell proteomic pattern by mass spectrometry and the phosphoproteomic pattern by
a 2-DE approach coupled with anti-phosphoserine and anti-phosphotyrosine western blotting were studied.
Conclusions/Significance: Proteomic analysis identified only two proteins whose expression was significantly different in
treated cells versus control cells: nucleoside diphosphate kinase A (NDKA) and reticulocalbin-1 (RCN1), which were both
downregulated after 9 days of ATRA treatment. However, phosphoproteomic analysis identified 8 proteins that were
differentially serine-phosphorylated and 3 that were differentially tyrosine-phosphorylated after ATRA treatment. All
proteins were significantly regulated (at least 0.5-fold down-regulated). Our results suggest that differentially
phosphorylated proteins could be considered as more promising markers of differentiation for NB than differentially
expressed proteins.
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Introduction
Neuroblastic tumors account for 9–10% of pediatric tumors and
neuroblastoma (NB) is the most frequent extra-cranial solid tumor
and the first cause of death in pre-school age children [1]. NB is
heterogenous in nature and mirrors the variety of cells that originate
from the embryonic neural crest. These cells are capable of
differentiating into an assortment of cells, including peripheral
neurons and melanocytes [2,3,4,5,6]. NB is a tumor composed of
undifferentiated or poorly differentiated neuroblasts. The arrested
differentiation of neuroblasts is apparently an early event in the
pathogenesis of NB [7]. According to the International Neuroblas-
toma Staging System, NB is classified into 4 stages: 1, 2A–B, 3 and
4, depending on the extent of spreading. Each stage is characterized
by different overall survival [1]. Prognostic factors for NB are
availableandwidelyappliedinpediatriconcology.Factorscurrently
used for risk stratification are histology (according to the
International Neuroblastoma Pathology Classification [INPC] and
the mitosis karyorrhexis index), proto-oncogene MYCN amplifica-
tion, deletion of the short arm of chromosome 1 and ploidy (cellular
deoxyribonucleic acid [DNA] content) [8]. However, markers that
identify areas of cellular differentiation/maturation on histological
sections and with more sensitivity or precocity than morphology
alone might provide additional factors and help to stratify patients
according to risk groups. Like other tumors, NB can regress
spontaneously and occurs at a higher frequency in NB than in any
other type of cancer. HNK-1, Trk-A, H-Ras, GRP78, GRP75 and
calreticulin, are biologic factors already identified that predicted a
favorable outcome for NB patients associated with the differenti-
ation or regression of NB cells at early clinical stages [9,10].
Spontaneous regression is most frequently observed in a particular
subset of disseminated MYCN single-copy NB [non-amplified
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category includes patients up to one year of age, showing metastatic
tumors at onset that infiltrate skin, liver and/or bone marrow, but
not bone [1,12]. Stage 4S NB is one of the major puzzles for
oncologists.Patientswith disseminatedtumorsusually haveveryfew
chances to survive but stage 4S patients have an overall survival rate
that approximates 75% at five years. In most of these cases, the
tumor regresses spontaneously without any treatment or following
supportive treatment only. Regression of this tumor is probably
associated with differentiation and/or activation of programmed
cell death [1]. Neuronal differentiation can be induced in neuronal
precursor cells, including a wide number of NB cell lines, by
exposure to all-trans-retinoic acid (ATRA), a retinoic acid isoform
compound commonly used for in vitro NB differentiation models
[5,13,14]. Specifically, exposure of cells to physiological concentra-
tions of ATRA: (i) increases the number of cells bearing neuritic
processes and the length of these processes; (ii) generally inhibits cell
proliferation. ATRA exerts its effects on gene transcription by
binding to nuclear retinoic acid receptors (RARs) [5]. Although
non-genomic actions ofretinoidshave been proposed, they have not
been well investigated. In some cases, ATRA has been shown to
rapidly activate protein kinases including extracellular-regulated
kinase 1/2 [15,16,17,18,19] c-Jun N-terminal kinase [18,20], and
phosphatidylinositol 3-kinase [18,21]. Protein kinase activation has
been proposed to play a role in modulating neurite outgrowth [5]
but protein substrates have not been comprehensively studied. In
other cases retinoic acid has been shown to activate protein
phosphatases, such as mitogen-activated protein kinase phosphatase
I [22], protein phosphatase 2A and protein phosphatase 2B [23].
In this paper, we performed comparative proteomic and
phosphoproteomic analysis using a 2-DE approach coupled with
anti-phosphoserine and anti-phosphotyrosine western blotting.
Our model was the human SJ-NK-P NB cell line, treated or not
with ATRA for different times, to look for new potential
differentiation markers.
Results
Effects of ATRA on NB cell morphology
SJ-N-KP cells were treated with 10 mM ATRA for 24 hours
and 9 days. Figure 1 shows that after 24 hours few but consistent
differences in cell morphology were already appreciable in treated
cells, which started to elongate in comparison with control cells.
After 9 days, ATRA-treated cells exhibited an extensive network of
neurite process highlighting an evolution towards cell differenti-
ation. Therefore ATRA induced differentiation in the SJ-N-KP
NB cell line as expected.
Effect of ATRA on protein expression
In order to find new differentiation markers for NB, cell
differentiation was mimicked by treatment with 10 mM ATRA.
Comparative analysis of protein expression by 2-DE and mass
spectrometry was then performed in SJ-N-KP cells treated or not
for 24 hours or 9 days. Figure 2 shows representative 2-DE gel
images of control cells (Figure 2A, 24 h and 2C, 9 days) and
ATRA-treated cells (Fig. 2B, 24 h and 2D, 9 days) stained by
comassie. Protein separation was very efficient, allowing the study
of more than 500 protein spots. Tables 1 and 2 report the mass
spectrometry identifications of all differentially expressed proteins.
Seven proteins were differentially expressed (defined as at least 1.5-
fold upregulated or 0.5-fold downregulated) in samples treated
with ATRA for 24 hours (Table 1) and 5 proteins were
differentially expressed in samples treated for 9 days (Table 2).
However, the differential expression was statistically significant
only for two proteins and only at the longest treatment time:
nucleoside diphosphate kinase A (NDKA) (p,0.05) and reticulo-
calbin-1 (RCN1) (p,0.01), which were significantly downregulat-
ed after 9 days of ATRA treatment.
Effect of ATRA on protein phosphorylation
Since the phosphoproteome changes during cancer develop-
ment and phosphoproteins may constitute useful markers for the
early individuation of NB differentiation process, the effects of
ATRA on serine- and tyrosine- phosphorylation patterns in NB
cells were investigated. Firstly, we performed 1-DE analysis
followed by western blotting with anti-phosphoserine and anti-
phosphotyrosine antibodies in SJ-N-KP control cells and cells
treated with 10 mM ATRA for 30 min, 60 min, 3 h, 9 h, 24 h,
48 h or 9 days. Figure 3 shows that even though serine- and
tyrosine-phosphorylated proteins showed the same pattern in
ATRA-treated and untreated cells, protein phosphorylation levels
were significantly different in ATRA-treated cells at different times
in comparison with control cells as shown by densitometric
analysis of phosphoserine (panel A) and phosphotyrosine (panel B)
western blotting. To better understand the effects of ATRA on
protein phosphorylation, 2-DE analysis followed by western
blotting with anti-phosphoserine and anti-phosphotyrosine anti-
bodies was performed in cells treated or not with ATRA for
Figure 1. Phase contrast microscopy of NB cell line treated or not with ATRA. (A) SJ-N-KP control cells. (B) SJ-N-KP cells treated with 10 mM
ATRA for 24 hours. (C) SJ-N-KP cells treated with 10 mM ATRA for 9 days. Magnification: 406.
doi:10.1371/journal.pone.0018254.g001
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to identify the early changes induced by ATRA. Figure 4 shows
the representative phosphorylation pattern in control cells (Fig. 4A
and 4D), in cells treated with ATRA for 30 minutes (Fig. 4B and
4E) and in cells treated with ATRA for 60 minutes (Fig. 4C and
4F). Proteins found to be differentially phosphorylated and further
identified are evidenced. In agreement with a greater rate of serine
phosphorylation with respect to tyrosine phosphorylation, we
observed more spots in anti-phosphoserine (upper panels) than in
anti-phosphotyrosine (lower panels) western blots (even though
more proteins were loaded for anti-phosphotyrosine western blots
than for anti-phosphoserine blots). Table 3 reports the differen-
tially phosphorylated proteins identified by mass spectrometry. We
identified 1 protein that was differentially serine-phosphorylated
after ATRA treatment at 30 minutes, and 7 proteins (from 8 spots)
at 30 or 60 minutes. We also identified 1 protein (from 2 spots)
that was differentially tyrosine phosphorylated at 30 and
60 minutes, and 2 proteins at 60 minutes. All differences were
statistically significant (minimun cut-off: 0.5-fold down-regulation).
It is of note that after 30 and 60 minutes of ATRA treatment we
did not observe any changes in protein expression (Fig. 4 panels G,
H, I). The differentially phosphorylated proteins identified were
classified into different groups depending on their cellular
compartment localization and molecular function (Fig. 5 A and B).
Discussion
NB shows the highest rate of spontaneous regression of any
humantumor,mainlydueto differentiation and maturation ofthese
highly malignant cells into neurons [24]. It is of interest to study the
Figure 2. 2-DE analysis of NB cells treated or not with ATRA. Representative image from three independent experiments of coomassie-
stained 2-DE patterns of NB cell line SJ-N-KP: (A) 24 h control cells; (B) 24 h ATRA treatment; (C) 9 days control cells; (D) 9 days ATRA treatment.
Proteins were separated using 17-cm, pH-4–7 strips followed by SDSPAGE on 10%, 18620-cm gels. Proteins showing apparent differential expression
were identified by progressive numbers on the black squares. Corresponding identifications are reported in Table 1 and 2.
doi:10.1371/journal.pone.0018254.g002
Phosphoproteins as Differentiation Markers in NB
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e18254molecular pathways driving spontaneous regression in NB to
unravel the molecular basis of NB development, to look for new
potential differentiation markers and to determine the differentia-
tiontherapies that can be used to treat patients. Proteome analysis is
useful to identify differentially expressed proteins as possible new
biomarkers, and the analysis of protein phosphorylation allows the
study of the early events in the differentiation process, being thus an
important goal in the identification of new early expressed
biomarkers. Phosphorylation events in cellular signaling cascades
triggered by a variety of cellular stimuli modulate protein function,
leading to diverse cellular outcomes including cell division, growth,
differentiation and death. Abnormal regulation of protein phos-
phorylation due to mutation or overexpression of signaling proteins
often results in various disease states [25]. Phosphoproteome
changesoccurringduringcancerdevelopmentandphosphoproteins
could constitute biomarkers useful for cancer diagnostics and
therapeutics [26]. It is well-known that the phosphotyrosine
proteome in breast and liver cancer is indeed distinct [26]. In
addition, Khadjavi et al. recently demonstrated that the protein
tyrosine phosphorylation pattern is profoundly different in bladder
cancer tissue biopsies in comparison with the surrounding healthy
tissues and that phosphorylated proteins may represent a new
valuable class of bladder cancer urinary markers (Khadjavi et al., in
press). In this report, the phosphorylation status of ATRA-treated
NB cells was studied using a 2-DE approach coupled with anti-
phosphoserine and anti-phosphotyrosine western blotting and by
mass spectrometry. Recent advances in mass spectrometry have
clearly revolutionized the studies of phosphoprotein biochemistry,
but gel electrophoresis-based proteomics remains one of the most
appropriate methods for analyzing protein phosphorylation [27].
The present study identified several proteins with strikingly different
expression or phosphorylation patterns in ATRA-treated NB cells
with respect to control cells. However, more intense and evident
changes in ATRA-treated cells were found in their protein
Table 1. Proteins differentially expressed in neuroblastoma cell line following 24 h ATRA treatment as identified by MALDI-Tof MS.
Spot
number
a Identified protein
Accession
number
MW
(Da)
b pI
c
Mascot
Score
Matching Peptide/
Searched
d
Coverage
(%)
e
Treated/Untreated
Ratio ± SD
f
1 Calreticulin precursor P27797 48283 4.29 121 11/25 27 3.164.5
2 Vimentin P08670 53676 5.06 137 13/25 36 2.261.7
3 Vimentin P08670 53676 5.06 88 11/25 24 21.2635.1
4 78 kDa glucose-regulated protein precursor P11021 72402 5.07 77 9/25 19 1.961.6
5 Ubiquilin-2 Q9UHD9 65655 5.15 74 9/25 17 465.3
6 Protein disulfide-isomerase precursor P07237 57480 4.76 127 12/25 30 3.961.8
7 ATP synthase subunit beta, mitochondrial
precursor
P06576 56525 5.26 163 16/25 32 2.461.2
8 Glutathione S-transferase P P09211 23569 5.43 56 5/25 27 3.162.1
aSpot number were defined according to spot positions in 2-DE in Fig. 2.
bMW, molecular weight.
cpI, isoelectric point.
dNumber of matched mass values on number of total mass values searched.
eThe sequence coverage, which is calculated as the percentage of identified sequence to the complete sequence of the matched protein.
fRatio between level of expression in treated and untreated cells. Standard deviation is indicated. For the significance two-sided Student’s t test was used (* p,0.05,
** p,0.01).
doi:10.1371/journal.pone.0018254.t001
Table 2. Proteins differentially expressed in neuroblastoma cell line following 9 days ATRA treatment as identified by MALDI-Tof
MS.
Spot
number
a Identified protein
Accession
number MW (Da)
b pI
c
Mascot
Score
Matching Peptide/
Searched
d
Coverage
(%)
e
Treated/Untreated Ratio
± SD
f
9 Reticulocalbin-1 precursor Q15293 38866 4.86 61 6/25 20 0.460.1**
10 Nucleoside diphosphate kinase A P15531 17309 5.83 76 6/25 40 0.360.3*
11 Vimentin P08670 53676 5.06 95 10/25 26 3.964.4
12 Nucleophosmin Q96EA5 32726 4.64 60 5/25 25 3.962.9
13 Deoxyuridine 59-triphosphate
nucleotidohydrolase,
mitochondrial precursor
P33316 26975 9.65 80 6/25 34 1.961.8
aSpot number were defined according to spot positions in 2-DE in Fig. 2.
bMW, molecular weight.
cpI, isoelectric point.
dNumber of matched mass values on number of total mass values searched.
eThe sequence coverage, which is calculated as the percentage of identified sequence to the complete sequence of the matched protein.
fRatio between level of expression in treated and untreated cells. Standard deviation is indicated. For the significance two-sided Student’s t test was used (* p,0.05,
** p,0.01).
doi:10.1371/journal.pone.0018254.t002
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ylated already after 30 or 60 min treatment. In contrast, just 2
proteins were differentially expressed 9 days after treatment). The
lower number of statistically significant differences among proteins
expressed after 24 h and 9 days of treatment can be ascribed to the
observed variability between different cell preparations [28] related
to the tendency of NB cells to undergo spontaneous differentiation
in vitro [29]. The 2-DE phosphorylation pattern showed more
phosphoserine than phosphotyrosine residues according to the
major presence of aminoacid residues modified by phosphorylation
in serine (P-Ser>90%) than in tyrosine (P-Tyr>0.05%) [30]. The
response observed to ATRA treatment is not an on/off-like
response, but a variation in phosphorylation levels. This is in
accordance with the fact that the biologically significant aspect of
protein phosphorylation is especially related to the quantitative
variation of the state of phosphorylation on a given protein or
groupsofproteins[27].Curiously,here almostallproteinsidentified
that changed their phosphorylation levels in a statistically significant
way tended to decrease their phosphorylation levels following
ATRA treatment. This observation leads us to postulate the
involvement of protein phosphatases in NB differentiation. At
present, few data supporting this hypothesis are available. Den
Hertog et al. demonstrated that receptor protein tyrosine
phosphatase a expression is enhanced during neuronal differenti-
ation of embryonal carcinoma cells and N1E-115 NB cells [31].
Additionally, Haque et al. reported the upregulation of the activities
of both protein phosphatase 1 and protein phosphatase 2A in NB
cells after differentiation [32]. Major studies are undoubtedly
required to confirm this intriguing hypothesis. Thus, the evidence
showed in the present work might be placed within this context and
further investigation on the role of phosphatases in NB differenti-
ation is warranted. On the other hand, a large body of data reports
that ATRA treatment promotes protein phosphorylation through
the activation of several protein kinases [15,16,17,18,19,20,21].
However, in many cases the biological meaning of these
phosphorylative events needs to be elucidated.
In the present work, among the proteins with decreased
phosphorylation levels at the beginning of differentiation program
induced by ATRA, we found 3 mitochondrial proteins: stress-70
protein, ATP synthase and ATP-dependent Clp protease. It has
been already demonstrated that the mitochondrial phosphopro-
teome comprises proteins belonging to different functional
groups: metabolism, apoptosis, cell cycle, cell maintenance,
transcription/translation, structural, chaperones and stress re-
sponse [33]. As shown by Pagliarini et al., reversible phosphor-
ylation is becoming an important means of regulating mitochon-
drial functions [34]. In this case, decreased stress-70 protein
serine-phosphorylation levels can be related to the observed
inhibition of human NB growth induced by ATRA [5,14], in
agreement with evidence showing that, on the contrary, high
levels of stress-70 protein serine-phosphorylated accelerate
centrosome duplication and cellular mitosis [35]. The role of
phosphorylation of the ATP synthase b subunit has been
elucidated, indicating that the phosphorylation event precedes
the recruitment of mitochondrial 14-3-3 proteins with consequent
inhibition of ATP synthesis [36]. Some data are apparently in
contrast with the present evidence showing a decrease of
phosphorylation levels of the b subunit of the ATP synthase
following ATRA treatment. For example, increased phosphory-
lation of mitochondrial ATP synthase beta-chain in apoptotic and
in terminally differentiated HL-60 cells has been demonstrated
[37]. Of note, in the cited paper, ATRA treatment was prolonged
for 120 hours. ATP-dependent Clp protease was already seen to
be phosphorylated on serine in a leukemia cell line [38] but no
data correlating protein phosphorylation and differentiation are
currently available.
Among the differentially phosphorylated proteins identified
here, a second group belonged to ER proteins: serine-
Figure 3. 1-DE western blot analysis of NB cells treated or not with ATRA. Representative western blot (of three independent experiments)
with anti-phosphoserine (A) and anti-phosphotyrosine (B) antibodies. SJ-N-KP cells were treated with ATRA 10 mM for 30, 60 minutes, 3, 9, 24,
48 hours and 9 days. Control cells (c) were not treated. 15 mg of proteins were analysed on 10% SDS-polyacrylamide gel. Western blot analysis with
anti-actin antibodies was performed on the same membranes and used for data normalization. Data (means 6 SD) expressed as densitometric units
are shown in the lower corner of panels A and B. Significance of the differences between controls and ATRA treated cells: p#0.05.
doi:10.1371/journal.pone.0018254.g003
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phorylated protein disulfide-isomerase A3 and tyrosine-phos-
phorylated 78 kDa glucose-regulated protein. As described
below, all these proteins are involved in the ER stress response,
which is notably induced by retinoic acid [39,40]. Protein
disulfide-isomerase A6 phosphorylation on serine is well-
documented [41,42,43,44] and there is evidence that this
protein is serine-phosphorylated in G1 and M phases [44]; thus
a decrease of phosphorylation of this protein fits well with data
showing the inhibition of proliferation induced by ATRA
[5,14]. Phosphorylation of disulfide-isomerase A3 is induced by
av a r i e t yo fs t i m u l is u c ha sl e p t i ni nt h el i v e r ,a n g i o t e n s i nI Ii n
smooth muscle cells and gamma knife surgery in the brain; it is
thought that the subcellular localization of protein disulfide-
isomerase A3 is regulated by the phosphorylation of the tyrosine
and serine residues [45]; however no data correlating protein
phosphorylation and differentiation are available. Finally, it is
well known that 78 kDa glucose-regulated protein can be
tyrosine phosphorylated; it is a Src substrate [46] which must
be tyrosine-phosphosylation for activation of PAK, a kinase
important in mobility of malignant cells and proliferation [47].
Therefore the observed dephosphorylation of the 78 kDa
glucose-regulated protein couldb el i n k e dt od a t as h o w i n gt h e
inhibition of proliferation induced by ATRA [5,14]. Another
category of proteins identified as differentially phosphorylated
are the cytoskeleton proteins actin and vimentin. Both are
known to be phosphorylated [48,49,50,51,52] in conjunction
with cytoskeleton reorganization, which may conceivably occur
during differentiation [53]. In particular, serine-phosphorylation
of vimentin by Rho-associated kinase is involved in the agonist-
induced neurite retraction of neuronal cells in NB [50]; these
data are in accordance with our observation of a a diminution of
phosphorylation levels following differentiation in NB leading to
neurite spreading. Moreover, the expression of vimentin also
seems to be involved in NB differentiation induced by ATRA,
b u tt h ed a t aa r en o te x h a u s t i v e[ 54,55]. Finally, eukaryotic
Figure 4. Phosphoproteome analysis of NB cell line treated or not with ATRA. Representative 2-DE western blot (of three independent
experiments) with anti-phosphoserine (A, B, C) and anti-phosphotyrosine (D, E, F) antibodies are shown. Proteins were separated using 7-cm, pH-4–7
strips followed by SDSPAGE on 10%, 867-cm gels. (A, D) SJ-N-KP control cells. (B, E) SJ-N-KP cells treated with 10 mM ATRA for 309.( C, F) SJ-N-KP cells
treated with 10 mM ATRA for 609. The black squares and circles give the position of identified protein spots that are differentially phosphorylated in
ATRA treated cells in comparison to control cells. The spot numbers correspond to the spot numbers listed in Table 3. Panels G, H and I show the
representative (of three independent experiments) coomassie-stained 2-DE patterns of NB cell line SJ-N-KP not treated (G) and treated with ATRA for
30 minutes (H) and for 60 minutes (I). 2-DE was performed as described above.
doi:10.1371/journal.pone.0018254.g004
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in the initiation of protein synthesis, was seen to be
phosphorylated on tyrosine residues in fibroblast and lung
cancer cell lines [56,57]; no data are available correlating its
phosphorylation and differentiation.
Protein localisation is certainly important, but it also
interesting to classify the described proteins according to their
functions. Among the proteins identified as being differentially
phosphorylated in present work, many are involved in folding
mechanisms: stress-70 protein, ATP-dependent Clp protease,
protein disulfide-isomerase A6, protein disulfide-isomerase A3,
78 kDa glucose-regulated protein. This is compatible with the
reorganization of cellular status that occurs during differentiation
with probable concomitant synthesis of new proteins. On the
other hand, other proteins are glucose-related: protein disulfide-
isomerase A3, 78 kDa glucose-regulated protein and stress-70
protein. 78 kDa glucose-regulated protein is essential for the
differentiation of NB cells [9]. Moreover, it is known that 78 kDa
glucose-regulated protein is also influenced by ATRA, but the
effect appears to be strictly connected to cell origin, as ATRA
downregulates 78 kDa glucose-regulated protein expression in
foetal bovine chondrocytes [58] but upregulates its expression in
hepatocarcinoma cells [59]. Stress-70 protein and protein
disulfide-isomerase A3 have already been correlated with ATRA
and differentiation, being overexpressed in NB cells following
ATRA treatment [9,10].
Table 3. Proteins differentially phosphorylated in neuroblastoma cell line following ATRA treatment as identified by MALDI-Tof
MS.
Spot
number
a Identified protein
Accession
number
MW
(Da)
b pI
c
Mascot
Score
Matching
Peptide/
Searched
d
Coverage
(%)
e
p-Ser 309:
Treated/Untreated
Ratio ± SD
f
p-Ser 609:
Treated/
Untreated
Ratio ± SD
f
p-Tyr 309:
Treated/
Untreated
Ratio ± SD
f
p-Tyr 609:
Treated/
Untreated
Ratio ± SD
f
1 Stress-70 protein,
mitochondrial precursor
P38646 73920 5.87 85 11/25 15 0.360.3** 0.560.4
2 ATP-dependent Clp
protease ATP-binding
subunit ClpX-like,
mitochondrial precursor
O76031 69922 7.51 57 6/25 14 0.660.9 0.460.3*
3 Actin, cytoplasmic 1 P60709 42052 5.29 124 11/25 36 0.560.4 0.460.2*
Actin, cytoplasmic 2 P63261 42108 5.31 124 11/25 36
4 Actin, cytoplasmic 1 P60709 42052 5.29 96 8/25 26 0.260.4*
Actin, cytoplasmic 2 P63261 42108 5.31 96 8/25 26
5 Actin, cytoplasmic 1 P60709 42052 5.29 77 8/25 26 0.160.1**
Actin, cytoplasmic 2 P63261 42108 5.31 77 8/25 26
6 ATP synthase subunit
beta, mitochondrial
precursor
P06576 56525 5.26 159 15/25 41 0.360.3* 0.460.8
Protein
disulfide-isomerase
A6 precursor
Q15084 48490 4.95 58 6/25 26
7 Vimentin P08670 53676 5.06 253 20/25 54 0.360.4 0.560.5*
8 Vimentin P08670 53676 5.06 58 7/25 22 0.160.2 0.260.4*
9 Protein
disulfide-isomerase
A3 precursor
P30101 57146 5.98 151 15/25 34 24.9642.4 0.260.1**
10 Protein
disulfide-isomerase
A3 precursor
P30101 57146 5.98 138 12/25 26 1.360.7 0.460.3*
11 78 kDa
glucose-regulated
protein precursor
P11021 72402 5.07 174 16/25 28 0.160.2** 161.4
12 78 kDa
glucose-regulated
protein precursor
P11021 72402 5.07 189 17/25 30 0.360.5** 0.160.1**
13 Eukaryotic translation
initiation factor
3 subunit 2
Q13347 36878 5.38 157 13/25 45 0.260.2*
aSpot number were defined according to spot positions in 2-DE in Fig. 4.
bMW, molecular weight.
cpI, isoelectric point.
dNumber of matched mass values on number of total mass values searched.
eThe sequence coverage, which is calculated as the percentage of identified sequence to the complete sequence of the matched protein.
fRatio between level of phosphorylation in treated and untreated cells. Standard deviation is indicated. For the significance two-sided Student’s t test was used
(* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0018254.t003
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be an interesting potential biomarker of early differentiation. A
future analysis of the phosphorylation status of proteins in NB
tissues utilizing specific phosphorylated-protein antibodies could
permit the validation of these proteins as candidates for
application in the clinical practice. The use of markers of
maturation could be very important to detect the onset of
differentiation and to choose the most appropriate clinical
treatment. Additionally, there is increasing interest in the
application of differentiation inducers in the treatment of NB,
possibly in order to mimick the differentiation process that occurs
in stadium 4S-tumours, which can regress spontaneously [7].
Thus, a more exhaustive comprehension of the phenomena
described in the present study can also help to better understand
the differentiation mechanisms in forms of NB that do not regress
spontaneously.
Materials and Methods
Chemicals and reagents
RPMI 1640, streptomycin, penicillin, ATRA, protease and
phosphatase inhibitors, ammonium persulfate (APS), bromophe-
nol blue, glycerol, N,N,N9,N9-tetramethylethylene-diamine
(TEMED), sodium dodecyl sulfate (SDS), TRIZMA, urea,
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonate
(CHAPS), dithiothreitol (DTT), iodoacetamide were purchased
from Sigma-Aldrich (St. Louis, MO, USA). DC Protein assay kit,
acrylamide, agarose, ready-made immobilized pH gradient (IPG)
strip (7- and 17-cm IPG strips, pH 4–7), enhanced chemilumi-
nescence kit were purchased from Bio-Rad (Hercules, CA, USA).
Ampholine pH 3.5–10 and 5–8 were obtained from GE
Healthcare (MI, ITALY). Fetal bovine serum USA Origin was
purchased from EuroClone (Paignton, UK). PVDF membrane
Figure 5. Distribution of identified spots corresponding to proteins differentially phosphorylated following ATRA treatment.
Distribution is shown according to proteins cellular compartment localization and their molecular function.
doi:10.1371/journal.pone.0018254.g005
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anti-phosphoserine PSR-45, anti-phosphotyrosine PY-20 and
anti-goat IgG horseradish-peroxidase-labeled were purchased
from Sigma, anti-phosphotyrosine PY99 and anti-actin from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-
mouse IgG horseradish-peroxidas e-labeled from GE Healthcare
Bio-Sciences.
Cell culture and ATRA treatment
Established NB human cell line SJ-N-KP [60] was cultured at
37uC, 5% CO2 in RPMI 1640 supplemented with 10% heat
inactivated foetal bovine serum USA Origin, 100 mg/mL
streptomycin and 100 U/mL penicillin. Cells were cultured in
the presence or not of 10 mM [61,62] ATRA at different times:
24 hours and 9 days for morphological analysis; 30, 60 minutes,
24 hours and 9 days for protein expression analysis experiments;
30, 60 minutes, 3, 9, 24, 48 hours or 9 days for protein
phosphorylation analysis experiments. The medium was changed
every two days.
Morphological analysis
Subconfluent cells were treated or not with 10 mM ATRA, as
previously described. Cell morphology was investigated with phase
contrast microscopy (microscope Axiovert 35, Zeiss) and photo-
graphed with magnification 406 with a digital camera (Coolpix
N25, Nikon).
Sample preparation for protein expression and
phosphorylation analysis experiments
One confluent dish (150625 mm) was washed two times in PBS
harvested with a scraper and suspended in 0.5 ml of a solution
containing 8 M urea, 2% w/v CHAPS, 40 mM Trizma, protease
and phosphatase inhibitors. The sample was incubated O.N. at
4uC and spun down at 13,800 g for 10 min at 4uC. The clear
supernatant was removed, quantified with DC Protein assay kit
and stored at 220uC until analysis.
Mono-dimensional electrophoresis (1-DE)
After adding of Laemmli buffer [63], samples were boiled for
5 min and 60 mM final concentration DTT, was added. 15 mgo f
each protein sample were analysed on 10% SDS-polyacrylamide
gel on the Mini Protean system (Bio-Rad).
Two-dimensional gel electrophoresis (2-DE)
2-DE was performed using ready-made IPG strip (17- and 7-cm
IPG strips, pH 4–7). Each sample (150 mg of protein for large
analytical gels and 2 mg for large preparative gels, 100 mg for anti-
phosphoserine western blotting and 300 mg for anti-phosphotyr-
osine western blotting and preparative gels) was applied onto an
IPG gel by in-gel rehydration for 20 h, adding DTT 1% w/v, final
concentration and Ampholine pH 3.5–10, 2% v/v, final concen-
tration. Isoelectric focusing was carried out in a Protean IEF cell
apparatus (Bio-Rad). Briefly, focusing for 7-cm IPG strips was
started at 250 V, and the voltage was progressively increased to
4000 V until a maximum of 25000 V-h was reached; for 17-cm
IPG strips, the voltage was increased to 9000 V until a maximum
of 60000 V-h was reached. Focusing was performed at 18uC with
a limit of 50 mA per strip. Subsequently the IPG strips were
equilibrated under continuous shaking for 15 min in equilibration
buffer 1 (6 M urea, 2% w/v SDS, 0.05 M Tris–HCl pH 8.8, 20%
v/v glycerol, 1% w/v DTT) and for 12 min in equilibration buffer
2 (6 M urea, 2% w/v SDS, 0.05 M Tris–HCl pH 8.8, 20% v/v
glycerol, 2.5% w/v iodoacetamide). For small format second
dimension, 86760.1 cm 10% acrylamide gels were run on the
Mini Protean system (Bio-Rad). For large format second
dimension, 1862060.1 cm 10% acrylamide gels were run on
the Bio-Rad XI cell. Electrophoresis was performed for 30 min at
50 V and then was continued at 100 V until the Bromophenol
blue front reached the lower limit of the gel. Analytical gels were
stained with silver staining as described [64] and preparative gels
with colloidal Coomassie (18% v/v ethanol, 15% w/v ammonium
sulfate, 2% v/v phosphoric acid, 0.2% w/v Coomassie G-250) for
48 h and destained with water.
Western blotting
Small format gels were transferred to a PVDF membrane.
Membranes were blocked with 3% w/v BSA in PBST (PBS
supplemented by polyoxyethylenesorbitan monolaurate [Tween
20] 0.1% v/v) for 1 h and then membranes were washed three
times with PBST and probed with a 1:400 dilution of anti-
phosphoserine PSR-45 or 1:400 dilution of two mixed 1:1 anti-
phosphotyrosine (PY20 and PY99) O.N. at 4uC. Membranes were
washed six times with PBST, incubated for 1 hour with a 1:10000
dilution of anti-mouse IgG horseradish-peroxidase-labeled anti-
body and immunoreactivity was detected with an enhanced
chemiluminescence kit. Afterwards membranes with 1-DE analysis
were stripped (2 hours washing with glycine 20 mM pH 2.2,
Tween 1% v/v, SDS 0.1% w/v) and probed with 1:100 dilution of
anti-actin antibodies for normalization of the data.
Image analysis
1-DE densitometric analysis was performed using ImageJ
software (version 1.44, free). 2-DE image analysis was performed
using PD-Quest software (version 7.2, Bio-Rad) according to the
manufacturer’s instructions. Normalization of each individual spot
was performed according to the total quantity of the valid spots in
each gel, after subtraction of the background values. The spot
volume was used as the analysis parameter to quantify protein
expression or phosphorylation.
Protein identification by mass spectrometry and
database search
Coomassie G-stained spots were excised from 2-DE preparative
gels; destaining and in-gel enzymatic digestion were performed as
previously described [65]. Briefly each spot was destained with
100 ml of 50% v/v acetonitrile in 5 mM ammonium bicarbonate
and dried with 100 ml of acetonitrile. Each dried gel piece was
rehydrated for 40 min at 4uCi n1 0 ml of a digestion buffer
containing 5 mM ammonium bicarbonate, and 10 ng/mlo f
trypsin. Digestion was allowed to proceed overnight at 37uC and
the peptides mixtures were stored at 4uC until assayed. All digests
were analyzed by MALDI-TOF (TofSpec SE, MicroMass)
equipped with a delayed extraction unit. Peptides solution was
prepared with equal volumes of saturated a-cyano-4-hydroxycin-
namic acid solution in 40% v/v acetonitrile-0.1% v/v trifluor-
oacetic acid. The MALDI-TOF was calibrated with a mix of PEG
(PEG 1000, 2000 and 3000 with the ratio 1:1:2) and mass spectra
were acquired in the positive-ion mode. Peak lists were generated
with ProteinLynx Data Preparation (ProteinLynx Global Server
2.2.5) using the following parameters: external calibration with
lock mass using mass 2465.1989 Da of ACTH, background
subtract type adaptive combining all scans, performing deisotoping
with a threshold of 1%. The 25 most intense masses were used for
database searches against the SWISSPROT database (release
2011-01 of 11-Jan-11) using the free search program MASCOT
2.3.02 (http://www.matrixscience.com). The following parame-
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missed cleavage by trypsin, carbamidomethylation of cysteine as
fixed modification, methionine oxidation and serine or tyrosine
phosphorylation (only for differential phosphoproteomic analysis)
as variable modifications and maximum error allowed 100 ppm.
Were taken on to consideration only protein with a Mascot score
.55.
Statistical analysis
Data from densitometric analysis were used as values of proteins
phosphorylation in 1-DE experiments. Data from image analysis
were used as values of protein expression or phosphorylation in 2-
DE experiments. To verify the significance of the variations of
expression and phosphorylation of proteins in ATRA treated cells
versus control cells, two-sided Student’s t test was used. Experiments
were performed in triplicate. Statistical significance was set at p-
values#0.05. In 2-DE experiments proteins were classified as
differentially expressed or phosphorylated if ratio in spot intensity
between treated cells and control cells was greater than 1.5-fold
(protein overexpressed or overphosphorylated) or lower than 0.5-
fold (protein underexpressed or underphosphorylated).
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